Expertise in
15
conditions

Dr. Shreya S. Sinha

Oncology
Maryland Oncology Hematology P.A.
11886 Healing Way Ste 701, 
Silver Spring, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Maryland Oncology Hematology P.A.
11886 Healing Way Ste 701, 
Silver Spring, MD 

Overview

Shreya Sinha is an Oncologist practicing medicine in Silver Spring, Maryland.

Dr. Sinha is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Appendix Cancer, Familial Colorectal Cancer, and Muscle Invasive Bladder Cancer.

She is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 5 clinical trials. Dr. Sinha is currently accepting new patients.

Specialties

Oncology

Hospital Affiliations

Suburban Hospital
Holy Cross Germantown Hospital
Adventist Healthcare Shady Grove Medical Center
Holy Cross Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Maryland Oncology Hematology P.A.
11886 Healing Way Ste 701, Silver Spring, MD 20904

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
View 4 Less Clinical Trials

9 Total Publications

Clinical decision making during supervised endotracheal intubations in academic emergency medicine.
Clinical decision making during supervised endotracheal intubations in academic emergency medicine.
Journal: The American journal of emergency medicine
Published: August 12, 2025
Similar Doctors
Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

MedStar Georgetown University Hospital

3800 Reservoir Rd NW, 
Washington, DC 
 (11.5 miles away)
202-444-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Cheson is an Oncologist practicing medicine in Washington, Washington, D.c.. Dr. Cheson is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Non-Hodgkin Lymphoma. Dr. Cheson is currently accepting new patients.

Expertise in
19
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Expertise in
19
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Referral may be required

Office

8906 Bradmoor Dr, 
Bethesda, MD 
 (9.4 miles away)
301-496-7387
Languages Spoken:
English

Brigitte Widemann is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Widemann is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Medullary Thyroid Carcinoma, and Thyroidectomy.

Expertise in
13
conditions
Dr. Blanche P. Alter
Hematology | Oncology
Expertise in
13
conditions
Dr. Blanche P. Alter
Hematology | Oncology
Referral may be required

Office

9609 Medical Center Dr Rm 6E452, 
Rockville, MD 
 (12.4 miles away)
240-276-7239
Languages Spoken:
English

Blanche Alter is a Hematologist and an Oncologist practicing medicine in Rockville, Maryland. Dr. Alter is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Aplastic Anemia, Congenital Aplastic Anemia, Fanconi Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Frequently Asked Questions about Dr. Shreya S. Sinha

How do I make an appointment with Dr. Shreya S. Sinha?

You can book an appointment with Dr. Shreya S. Sinha by calling their office at 301-933-3216. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shreya S. Sinha a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shreya S. Sinha is classified as an Advanced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shreya S. Sinha specialize in?

While Dr. Shreya S. Sinha is a Oncology, they have specific expertise in Colorectal Cancer, Appendix Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Shreya S. Sinha participate in research or clinical trials?

Yes. Dr. Shreya S. Sinha has published 9 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Shreya S. Sinha's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Shreya S. Sinha accept my insurance?

Dr. Shreya S. Sinha accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 301-933-3216 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sinha's expertise for a condition
ConditionClose
      View All 15 Advanced Conditions
      View All 105 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile